Glioblastoma is a devastating CNS tumour for which no cure is presently available. We wondered if manipulation of Emx2, which normally antagonizes cortico-cerebral astrogenesis by inhibiting proliferation of astrocyte progenitors, may be employed to counteract it. We found that Emx2 overexpression induced the collapse of seven out of seven in vitro tested glioblastoma cell lines. Moreover, it suppressed four out of four of these lines in vivo. As proven by dedicated rescue assays, the antioncogenic activity of Emx2 originated from its impact on at least six metabolic nodes, which accounts for the robustness of its effect. Finally, in two out of two tested lines, the tumor culture collapse was also achieved when Emx2 was driven by a neural s...
Cancer is a deliberating disease that affects 1/3 of the population and kills approximately 40,000 A...
Glioblastoma multiforme (GBM) is the most aggressive, infiltrative brain cancer. Tumour recurrence i...
Background: Sprouty2 (SPRY2), a feedback regulator of receptor tyrosine kinase (RTK) signaling, has ...
Glioblastoma is a devastating CNS tumour for which no cure is presently available. We wondered if ma...
The homeodomain-containing transcription factor Emx2 encodes for a homeobox protein essential for te...
Abstract Background Glioblastoma (GB) is a highly invasive primary brain tumor that nearly always sy...
Cortico--‐cerebral astrogenesis is a tightly regulated process. Astrocytic outputs mainly depend on...
Glioblastoma multiforme (GBM) is the most aggressive and common form of primary brain tumor in adult...
Bromodomain and extraterminal domain (BET) proteins have emerged as therapeutic targets in multiple ...
Glioblastoma multiforme (GBM) is one of the most malignant primary brain tumors with an aggressive p...
Patients diagnosed with Glioblastoma multiforme (GBM) only survive a median time of sixteen (16) mon...
Brain tumours kill more children and adults under 40 than any other cancer. Around half of primary b...
Background: Although several studies suggest that stromal fibroblasts mediate treatment resistance i...
Glioblastoma multiforme (GBM), designated as World Health Organization (WHO) grade IV astrocytoma, i...
Glioblastoma Multiforme (GBM) is the most aggressive and malignant form of brain tumors. The therape...
Cancer is a deliberating disease that affects 1/3 of the population and kills approximately 40,000 A...
Glioblastoma multiforme (GBM) is the most aggressive, infiltrative brain cancer. Tumour recurrence i...
Background: Sprouty2 (SPRY2), a feedback regulator of receptor tyrosine kinase (RTK) signaling, has ...
Glioblastoma is a devastating CNS tumour for which no cure is presently available. We wondered if ma...
The homeodomain-containing transcription factor Emx2 encodes for a homeobox protein essential for te...
Abstract Background Glioblastoma (GB) is a highly invasive primary brain tumor that nearly always sy...
Cortico--‐cerebral astrogenesis is a tightly regulated process. Astrocytic outputs mainly depend on...
Glioblastoma multiforme (GBM) is the most aggressive and common form of primary brain tumor in adult...
Bromodomain and extraterminal domain (BET) proteins have emerged as therapeutic targets in multiple ...
Glioblastoma multiforme (GBM) is one of the most malignant primary brain tumors with an aggressive p...
Patients diagnosed with Glioblastoma multiforme (GBM) only survive a median time of sixteen (16) mon...
Brain tumours kill more children and adults under 40 than any other cancer. Around half of primary b...
Background: Although several studies suggest that stromal fibroblasts mediate treatment resistance i...
Glioblastoma multiforme (GBM), designated as World Health Organization (WHO) grade IV astrocytoma, i...
Glioblastoma Multiforme (GBM) is the most aggressive and malignant form of brain tumors. The therape...
Cancer is a deliberating disease that affects 1/3 of the population and kills approximately 40,000 A...
Glioblastoma multiforme (GBM) is the most aggressive, infiltrative brain cancer. Tumour recurrence i...
Background: Sprouty2 (SPRY2), a feedback regulator of receptor tyrosine kinase (RTK) signaling, has ...